SCYNEXIS (LTS:0L49) Other Long-Term Liabilities : $12.2 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Other Long-Term Liabilities?

SCYNEXIS's other long-term liabilities for the quarter that ended in Mar. 2024 was $12.2 Mil.

SCYNEXIS's quarterly other long-term liabilities declined from Sep. 2023 ($23.6 Mil) to Dec. 2023 ($21.7 Mil) and declined from Dec. 2023 ($21.7 Mil) to Mar. 2024 ($12.2 Mil).

SCYNEXIS's annual other long-term liabilities declined from Dec. 2021 ($21.4 Mil) to Dec. 2022 ($18.6 Mil) but then increased from Dec. 2022 ($18.6 Mil) to Dec. 2023 ($21.7 Mil).

SCYNEXIS Other Long-Term Liabilities Historical Data

The historical data trend for SCYNEXIS's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Other Long-Term Liabilities Chart

SCYNEXIS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

SCYNEXIS Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

SCYNEXIS Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

SCYNEXIS Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS (LTS:0L49) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

SCYX:USA 135A:Germany

Address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548

Website

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines